Abstract
Immunization involving a DNA vaccine prime followed by an adenovirus type 5 (Ad5) boost elicited a protective immune response against SHIV challenge in monkeys. However, the hepatocellular tropism of Ad5 limits the safety of this viral vector. This study examines the safety and immunogenicity of a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) in BALB/c mice and rhesus monkeys. This novel Ad5/35 vector showed minimal hepatotoxicity after intramuscular administration with the novel Ad5/35 vector. In addition, an Ad5/35 vector expressing HIV Env gp160 protein (Ad5/35-HIV) generated strong HIV-specific immune responses in both animal models. Priming with a DNA vaccine followed by Ad5/35-HIV boosting yielded protection against a gp160-expressing vaccinia virus challenge in BALB/c mice. The Ad5/35-HIV vector was significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector. These findings indicate that an Ad5/35 vector-based HIV vaccine may be of considerable value for clinical use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bukawa H et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat Med 1995; 1: 681–685.
Barouch DH et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290: 486–492.
Robinson HL et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999; 5: 526–534.
Shiver JW et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415: 331–335.
Patterson LJ et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004; 78: 2212–2221.
Schnell MJ et al. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci USA 2000; 97: 3544–3549.
Mandl CW et al. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 1998; 4: 1438–1440.
Matano T et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199: 1709–1718.
Caley IJ et al. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 1999; 17: 3124–3135.
Xin KQ et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther 2002; 13: 1571–1581.
Xin KQ et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 2001; 12: 1047–1061.
Aldovini A, Young RA . Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 1991; 351: 479–482.
Someya K et al. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette–Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J Virol 2005; 79: 1452–1462.
Xin KQ et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 2003; 102: 223–228.
Sullivan NJ et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408: 605–609.
Amara RR et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76: 7625–7631.
Vogels R et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263–8271.
Havenga MJ et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002; 76: 4612–4620.
Roelvink PW et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909–7915.
Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T . Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003; 8: 813–821.
Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A . Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567–2583.
Adams JY et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002; 8: 891–897.
Thomas CE, Ehrhardt A, Kay MA . Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346–358.
Gao W, Robbins PD, Gambotto A . Human adenovirus type 35: nucleotide sequence and vector development. Gene Therapy 2003; 10: 1941–1949.
Gaggar A, Shayakhmetov DM, Lieber A . CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408–1412.
Mizuguchi H, Hayakawa T . Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 2002; 285: 69–77.
Seshidhar Reddy P et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003; 311: 384–393.
Jounai N et al. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J Gene Med 2003; 5: 609–617.
Maino VC, Picker LJ . Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 1998; 34: 207–215.
Letvin NL et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78: 7490–7497.
Barouch DH et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001; 75: 5151–5158.
Altman JD et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94–96.
Sullivan NJ et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424: 681–684.
Wadell G . Molecular epidemiology of human adenoviruses. Curr Top Microbiol Immunol 1984; 110: 191–220.
De Jong JC et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999; 37: 3940–3945.
Kostense S et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 2004; 18: 1213–1216.
Barouch DH et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172: 6290–6297.
Casimiro DR et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77: 6305–6313.
Morral N et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816–12821.
Hofmann C et al. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol 1999; 73: 6930–6936.
Farina SF et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001; 75: 11603–11613.
Moffatt S, Hays J, HogenEsch H, Mittal SK . Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 2000; 272: 159–167.
Pinto AR et al. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 2003; 171: 6774–6779.
Fitzgerald JC et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003; 170: 1416–1422.
Lemiale F et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003; 77: 10078–10087.
Xiang ZQ, Pasquini S, Ertl HC . Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J Immunol 1999; 162: 6716–6723.
Lieber A, He CY, Kirillova I, Kay MA . Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944–8960.
Bhaumik S, Gambhir SS . Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 2002; 99: 377–382.
Lipshutz GS et al. In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol Ther 2001; 3: 284–292.
Mochizuki N et al. An infectious DNA clone of HIV type 1 subtype C. AIDS Res Hum Retroviruses 1999; 15: 1321–1324.
Mukai T et al. Construction and characterization of an infectious molecular clone derived from the CRF01_AE primary isolate of HIV type 1. AIDS Res Hum Retroviruses 2002; 18: 585–589.
Acknowledgements
We are grateful to M Kawano, T Takeishi, and T Matsuda for their technical assistance and A De La Fuente for her secretarial assistance. This work was partially supported by a Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan, and the grant for 2005 Strategic Research Project (No. K17018) of Yokohama City University, Japan.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xin, KQ., Jounai, N., Someya, K. et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12, 1769–1777 (2005). https://doi.org/10.1038/sj.gt.3302590
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302590
Keywords
This article is cited by
-
Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C
Gene Therapy (2022)
-
Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck
Medical Microbiology and Immunology (2015)
-
Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination
Science China Life Sciences (2011)
-
Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys
Gene Therapy (2010)
-
Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy
Gene Therapy (2009)